Posted by Michael Wonder on 02 Aug 2018
NICE publishes final appraisal determination for Sanofi's Dupixent
1 August 2018 - Dupilumab (Dupixent) is used to treat adults with moderate to severe atopic dermatitis.
Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:
- the disease has not responded to at least one other systemic therapy, such as cyclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contra-indicated or not tolerated
- Sanofi provides dupilumab according to the commercial arrangement
